AESARA
AESARA is a digital-forward Value & Access agency that develops innovative and trusted solutions to power transformative patient access. It is recognized as one of the most disruptive consultancies in healthcare, with a deep understanding of the complex and evolving healthcare landscape. AESARA offers strategic HEOR and market access consulting, impactful tools, and expertise in evidence storytelling and communications to help clients optimize their access strategies and product uptake.
Industries
Nr. of Employees
small (1-50)
Products
Interactive evidence dossier platform
A digital, interactive evidence dossier product that structures clinical, economic and real-world evidence for rapid payer review and supports dynamic updates and multimedia content.
Payer insights center (panel & advisory capability)
A structured capability for convening current C-suite payers and HTA advisors to generate rapid, actionable payer intelligence and test value communications.
Interactive evidence dossier platform
A digital, interactive evidence dossier product that structures clinical, economic and real-world evidence for rapid payer review and supports dynamic updates and multimedia content.
Payer insights center (panel & advisory capability)
A structured capability for convening current C-suite payers and HTA advisors to generate rapid, actionable payer intelligence and test value communications.
Services
End-to-end consulting to define value propositions, evidence generation plans, pricing and reimbursement approaches for target markets.
Design and facilitation of payer panels and interviews to capture payer evidence needs, test value frameworks and optimize communications.
Creation of interactive, multimedia evidence dossiers that enable rapid navigation to key data, integration of RWE and easier extraction of tables/figures for payers.
Simulated negotiation exercises (including CMS/IRA scenarios) to test counteroffers, refine narratives and build cross-functional negotiation readiness.
Assessment and redesign of field market access teams, bespoke stakeholder mapping tools, CRM refresh and KPI/process design to enable local execution and cross-country sharing.
Cross-functional policy development and training to enable compliant dissemination of HCEI and pre-approval information to payers and similar entities.
End-to-end consulting to define value propositions, evidence generation plans, pricing and reimbursement approaches for target markets.
Design and facilitation of payer panels and interviews to capture payer evidence needs, test value frameworks and optimize communications.
Creation of interactive, multimedia evidence dossiers that enable rapid navigation to key data, integration of RWE and easier extraction of tables/figures for payers.
Simulated negotiation exercises (including CMS/IRA scenarios) to test counteroffers, refine narratives and build cross-functional negotiation readiness.
Assessment and redesign of field market access teams, bespoke stakeholder mapping tools, CRM refresh and KPI/process design to enable local execution and cross-country sharing.
Cross-functional policy development and training to enable compliant dissemination of HCEI and pre-approval information to payers and similar entities.
Expertise Areas
- Market access strategy
- Regulatory and HTA strategy
- Payer engagement and insights
- Health economics & outcomes research (HEOR)
Key Technologies
- Interactive digital evidence dossiers
- Data visualization and infographic design
- HEOR methods and cost-effectiveness modelling
- Real-world evidence generation and analytics
News & Updates
Guidance on how to effectively facilitate virtual advisory boards and workshops, including serving hors d'oeuvres, listening to learn, visual engagement, sharing airtime, and managing energy levels.
An overview of collaborative regulatory and health technology assessment (HTA) initiatives among Australia, Canada, and the UK, including work-sharing procedures, benefits, and strategic implications for biopharma innovators.
Insights on entering the US market, including the large patient population, regulatory landscape, and innovative payment models such as outcome-based payments and risk-sharing arrangements.
Discussion on the importance of understanding payer perspectives to improve market access, pricing, and reimbursement strategies, with insights from AESARA's expertise in HEOR and payer engagement.
Review of the legislative and regulatory developments in healthcare economic information (HCEI) and pre-approval product information exchange (PIE), including the impact of FDA guidance and law on proactive payor communications.
Strategies for originator companies to prepare for biosimilar entry, including identifying value differentiators, internal readiness, and shaping tender and contracting markets.
Guidance on how to effectively facilitate virtual advisory boards and workshops, including serving hors d'oeuvres, listening to learn, visual engagement, sharing airtime, and managing energy levels.
An overview of collaborative regulatory and health technology assessment (HTA) initiatives among Australia, Canada, and the UK, including work-sharing procedures, benefits, and strategic implications for biopharma innovators.
Insights on entering the US market, including the large patient population, regulatory landscape, and innovative payment models such as outcome-based payments and risk-sharing arrangements.
Discussion on the importance of understanding payer perspectives to improve market access, pricing, and reimbursement strategies, with insights from AESARA's expertise in HEOR and payer engagement.
Review of the legislative and regulatory developments in healthcare economic information (HCEI) and pre-approval product information exchange (PIE), including the impact of FDA guidance and law on proactive payor communications.
Strategies for originator companies to prepare for biosimilar entry, including identifying value differentiators, internal readiness, and shaping tender and contracting markets.